Having trouble accessing articles? Reset your cache.

Keytruda sales show how Merck can compete in China

Despite local competition from cheaper PD-1 inhibitors, Keytruda continues to drive Merck's growth in China and its revenue globally.

The immuno-oncology drug brought in $2.6 billion in global sales for the quarter, up 63% from 2Q18 at constant exchange rates and ahead of consensus estimates

Read the full 440 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers